<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325922</url>
  </required_header>
  <id_info>
    <org_study_id>CRD 274</org_study_id>
    <nct_id>NCT01325922</nct_id>
  </id_info>
  <brief_title>50/50% Tilt and Tuned Defibrillation Waveform</brief_title>
  <official_title>50/50% Tilt and Tune Defibrillation Waveforms Utilizing High Voltage Lead Integrity Check Impedance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Description The purpose of this study is to compare the defibrillation efficacy between&#xD;
      the 50/50% tilt biphasic waveform and the Tuned biphasic waveform utilizing High Voltage Lead&#xD;
      Integrity Check (HVLIC) impedance.&#xD;
&#xD;
      Hypothesis The Tuned waveform reduces defibrillation thresholds (DFTs) when compared to the&#xD;
      50/50% tilt waveform.&#xD;
&#xD;
      Study Methods&#xD;
&#xD;
        -  This is an acute, paired-sample, randomized (waveform testing sequence) study&#xD;
&#xD;
        -  Patients are implanted with an Food and Drug Administration (FDA) approved St. Jude&#xD;
           Medical (SJM) EpicTM+ DR/VR Implantable Cardioverter Defibrillator (or any other&#xD;
           standard output ICD after Epic+) and defibrillation lead system.&#xD;
&#xD;
        -  All study testing is completed at implant.&#xD;
&#xD;
        -  Patients are randomized to begin DFT testing with either the 50/50% tilt or Tuned&#xD;
           waveform.&#xD;
&#xD;
        -  The HVLIC feature is used to measure the high voltage lead impedance and to program the&#xD;
           Tuned and 50/50% tilt waveform pulse widths.&#xD;
&#xD;
        -  The DFT is determined by an optimized binary search method that is designed to reduce&#xD;
           the overall number of VF inductions to an average of 5.13 while maintaining very high&#xD;
           resolution and accuracy.&#xD;
&#xD;
        -  Total # of centers - 15 centers&#xD;
&#xD;
        -  Sample size - 60 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <condition>DFT Testing</condition>
  <arm_group>
    <arm_group_label>50/50% Tilt</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DFT Testing with a 50/50% tilt</intervention_name>
    <arm_group_label>50/50% Tilt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is a candidate for ICD implantation.&#xD;
&#xD;
          -  Patient is able to tolerate DFT testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a mechanical valve in the tricuspid position.&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
&#xD;
          -  Patient is less than 18 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Affairs</name_title>
    <organization>St. Jude Medical</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

